ArticleACS medicinal chemistry letters2023
Anti-infectives Developed as Racemic Drugs in the 21st Century: Norm or Exception?
Article in ACS medicinal chemistry letters, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Stereochemical Terminology in Chiral Drugs: Still Between Confusion and Misinterpretation.ACS medicinal chemistry letters · 2026Article
- From Hit to Lead: Systematic Optimization of the Quinazolinedione Scaffold as Potent and Noncytotoxic Antimalarial Agents.ACS omega · 2026Article
- The Death of the Strategy of Classical Chiral Switches Is an Exaggeration.ACS medicinal chemistry letters · 2024Article
- Chiral Switches of Tramadol Hydrochloride, a Potential Psychedelic Drug-Past and Future.ACS medicinal chemistry letters · 2024Article
- Chirality of New Drug Approvals (2013-2022): Trends and Perspectives.Journal of medicinal chemistry · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This viewpoint outlines the case for developing new chemical entities (NCEs) as racemates in infectious diseases and where both enantiomers and racemate retain similar on- and off-target activities as well as similar PK profiles. There are not major regulatory impediments for the development of a racemic drug, and minimizing the manufacturing costs becomes a particularly important objective when bringing an anti-infective therapeutic to the marketplace in the endemic settings of infectious diseases.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.